Cynata’s Cymerus™ MSCs Effective in Preclinical Model of Diabetic Wounds


May 31, 2018 / News & Media Releases

Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX: CYP) is pleased to announce that it has received positive data demonstrating the efficacy of its Cymerus™ mesenchymal stem cells (MSCs) in a preclinical model of diabetic wounds. The studies were conducted independently by the Cooperative Research Centre for Cell Therapy Manufacturing (CTM CRC) and were designed to compare cells from various sources.

Read More